Damora Therapeutics is trading 5.03% down at $27.54 amid a broader risk-off session, as higher oil prices, renewed U.S.-Iran tensions, elevated bond yields, and hawkish Federal Reserve expectations pressure growth-oriented equities.
- Major U.S. indexes are also lower.
- No new company-specific announcement was identified for August 31, 2026.
- Latest reported updates were its August 10 quarterly results and August 5 CLARITY-101 trial initiation.